These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 17220808)

  • 21. Impact of sirolimus treatment in kidney allograft recipients with prolonged cold ischemia times: 5-year outcomes.
    Boratynska M; Banasik M; Patrzalek D; Klinger M
    Exp Clin Transplant; 2008 Mar; 6(1):59-66. PubMed ID: 18405247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Five-year follow-up after late conversion from calcineurin inhibitors to sirolimus in patients with chronic renal allograft dysfunction.
    Krüger B; Fischereder M; Jauch KW; Graeb C; Hoffmann U; Böger CA; Banas B; Obed A; Schlitt HJ; Krämer BK
    Transplant Proc; 2007 Mar; 39(2):518-21. PubMed ID: 17362772
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abrogation of protein uptake through megalin-deficient proximal tubules does not safeguard against tubulointerstitial injury.
    Theilig F; Kriz W; Jerichow T; Schrade P; Hähnel B; Willnow T; Le Hir M; Bachmann S
    J Am Soc Nephrol; 2007 Jun; 18(6):1824-34. PubMed ID: 17460141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mitochondria are the major targets in albumin-induced apoptosis in proximal tubule cells.
    Erkan E; Devarajan P; Schwartz GJ
    J Am Soc Nephrol; 2007 Apr; 18(4):1199-208. PubMed ID: 17360944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sirolimus in chronic allograft nephropathy in pediatric recipients.
    Ibáñez JP; Monteverde ML; Diaz MA; Goldberg J; Turconi AF
    Pediatr Transplant; 2007 Nov; 11(7):777-80. PubMed ID: 17910656
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sirolimus modifies cholesterol homeostasis in hepatic cells: a potential molecular mechanism for sirolimus-associated dyslipidemia.
    Ma KL; Ruan XZ; Powis SH; Chen Y; Moorhead JF; Varghese Z
    Transplantation; 2007 Oct; 84(8):1029-36. PubMed ID: 17989609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD36 is a novel and potential anti-fibrogenic target in albumin-induced renal proximal tubule fibrosis.
    Yang YL; Lin SH; Chuang LY; Guh JY; Liao TN; Lee TC; Chang WT; Chang FR; Hung MY; Chiang TA; Hung CY
    J Cell Biochem; 2007 Jun; 101(3):735-44. PubMed ID: 17226761
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The paracellular shunt of proximal tubule.
    Weinstein AM; Windhager EE
    J Membr Biol; 2001 Dec; 184(3):241-5. PubMed ID: 11891548
    [No Abstract]   [Full Text] [Related]  

  • 29. Patient selection critical for calcineurin inhibitor withdrawal in pediatric kidney transplantation.
    Weintraub L; Li L; Kambham N; Alexander S; Concepcion W; Miller K; Wong C; Salvatierra O; Sarwal M
    Pediatr Transplant; 2008 Aug; 12(5):541-9. PubMed ID: 18564305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of murine lupus disease in (NZBxNZW)F1 mice by sirolimus treatment.
    Ramos-Barrón A; Piñera-Haces C; Gómez-Alamillo C; Santiuste-Torcida I; Ruiz JC; Buelta-Carrillo L; Merino R; de Francisco AL; Arias M
    Lupus; 2007; 16(10):775-81. PubMed ID: 17895299
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Albumin and proximal tubular cells--beyond endocytosis.
    Brunskill NJ
    Nephrol Dial Transplant; 2000 Nov; 15(11):1732-4. PubMed ID: 11071954
    [No Abstract]   [Full Text] [Related]  

  • 32. Sirolimus: defining nephrotoxicity in the renal transplant recipient.
    Tomlanovich SJ; Vincenti F
    Clin J Am Soc Nephrol; 2007 Mar; 2(2):198-9. PubMed ID: 17699406
    [No Abstract]   [Full Text] [Related]  

  • 33. Possible mechanism by which rapamycin increases cyclosporine nephrotoxicity.
    Cheng CH; Chang HR; Chiang CW; Shu KH; Chou MC
    Transplant Proc; 2008 Sep; 40(7):2373-5. PubMed ID: 18790238
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mammalian target of rapamycin inhibition prevents glomerular hypertrophy in a model of renal mass reduction.
    Rovira J; Arellano EM; Carreras J; Campos B; Vodenik B; Bañón-Maneus E; Ramírez-Bajo MJ; Moya-Rull D; Solé-González A; Hernández A; Revuelta I; Quintana LF; Howat WJ; Campistol JM; Diekmann F
    Transplantation; 2009 Sep; 88(5):646-52. PubMed ID: 19741461
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rapamycin promotes emergence of IL-10-secreting donor lymphocyte infusion-derived T cells without compromising their graft-versus-leukemia reactivity.
    Durakovic N; Radojcic V; Powell J; Luznik L
    Transplantation; 2007 Mar; 83(5):631-40. PubMed ID: 17353785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sirolimus ameliorates the enhanced expression of metalloproteinases in a rat model of autosomal dominant polycystic kidney disease.
    Berthier CC; Wahl PR; Le Hir M; Marti HP; Wagner U; Rehrauer H; Wüthrich RP; Serra AL
    Nephrol Dial Transplant; 2008 Mar; 23(3):880-9. PubMed ID: 18042615
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanisms of the ifosfamide-induced inhibition of endocytosis in the rat proximal kidney tubule.
    Yaseen Z; Michoudet C; Baverel G; Dubourg L
    Arch Toxicol; 2008 Sep; 82(9):607-14. PubMed ID: 18214444
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fluvastatin accelerates re-endothelialization impaired by local sirolimus treatment.
    Fukuda D; Enomoto S; Shirakawa I; Nagai R; Sata M
    Eur J Pharmacol; 2009 Jun; 612(1-3):87-92. PubMed ID: 19371739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Age-related change of endocytic receptors megalin and cubilin in the kidney in rats.
    Odera K; Goto S; Takahashi R
    Biogerontology; 2007 Oct; 8(5):505-15. PubMed ID: 17453355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sirolimus conversion experience in a single center.
    Wang HH; Huang JY; Chu SH; Chiang YJ; Liu KL; Lai PC
    Transplant Proc; 2008 Sep; 40(7):2209-10. PubMed ID: 18790194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.